Pemafibrate sodium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561812

CAS#: 950644-31-2 (sodium)

Description: Pemafibrate sodium is discontinued


Chemical Structure

img
Pemafibrate sodium
CAS# 950644-31-2 (sodium)

Theoretical Analysis

MedKoo Cat#: 561812
Name: Pemafibrate sodium
CAS#: 950644-31-2 (sodium)
Chemical Formula: C28H29N2NaO6
Exact Mass: 512.19
Molecular Weight: 512.530
Elemental Analysis: C, 65.62; H, 5.70; N, 5.47; Na, 4.49; O, 18.73

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 950644-31-2 (sodium)   848259-27-8 (free acid)  

Synonym: Pemafibrate sodium;

IUPAC/Chemical Name: Sodium (2R)-2-[3-[[1,3-benzoxazol-2-yl-[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoate

InChi Key: JSNXVHCVJMDNKW-VQIWEWKSSA-M

InChi Code: InChI=1S/C28H30N2O6.Na/c1-3-25(27(31)32)35-23-9-6-8-20(18-23)19-30(28-29-24-10-4-5-11-26(24)36-28)16-7-17-34-22-14-12-21(33-2)13-15-22;/h4-6,8-15,18,25H,3,7,16-17,19H2,1-2H3,(H,31,32);/q;+1/p-1/t25-;/m1./s1

SMILES Code: CC[C@@H](OC1=CC=CC(CN(C2=NC3=CC=CC=C3O2)CCCOC4=CC=C(OC)C=C4)=C1)C([O-])=O.[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 512.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y, Watada H, Suganami H, Ishibashi S. Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. Diabetes Care. 2018 Jan 3. pii: dc171589. doi: 10.2337/dc17-1589. [Epub ahead of print] PubMed PMID: 29298800.

2: Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2017 Dec 16. doi: 10.1007/s00535-017-1415-1. [Epub ahead of print] Review. PubMed PMID: 29247356.

3: Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S; K-877 Study Group. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol. 2017 Oct 28. pii: S1933-2874(17)30466-X. doi: 10.1016/j.jacl.2017.10.006. [Epub ahead of print] PubMed PMID: 29203092.

4: Fujioka Y. Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator K-877 (Pemafibrate) on Postprandial hyperlipidemia. J Atheroscler Thromb. 2017 Oct 18. doi: 10.5551/jat.ED088. [Epub ahead of print] PubMed PMID: 29046503.

5: Fruchart JC. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol. 2017 Oct 4;16(1):124. doi: 10.1186/s12933-017-0602-y. Review. PubMed PMID: 28978316; PubMed Central PMCID: PMC5628452.

6: Blair HA. Pemafibrate: First Global Approval. Drugs. 2017 Oct;77(16):1805-1810. doi: 10.1007/s40265-017-0818-x. PubMed PMID: 28929345.

7: Sairyo M, Kobayashi T, Masuda D, Kanno K, Zhu Y, Okada T, Koseki M, Ohama T, Nishida M, Sakata Y, Yamashita S. A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice. J Atheroscler Thromb. 2017 Aug 5. doi: 10.5551/jat.39693. [Epub ahead of print] PubMed PMID: 28781340.

8: Camejo G. Phase 2 clinical trials with K-877 (pemafibrate): A promising selective PPAR-α modulator for treatment of combined dyslipidemia. Atherosclerosis. 2017 Jun;261:163-164. doi: 10.1016/j.atherosclerosis.2017.04.013. Epub 2017 Apr 15. PubMed PMID: 28434555.

9: Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S; K-877 Study Group. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis. 2017 Jun;261:144-152. doi: 10.1016/j.atherosclerosis.2017.03.032. Epub 2017 Mar 24. PubMed PMID: 28410749.

10: Ferri N, Corsini A, Sirtori C, Ruscica M. PPAR-α agonists are still on the rise: an update on clinical and experimental findings. Expert Opin Investig Drugs. 2017 May;26(5):593-602. doi: 10.1080/13543784.2017.1312339. Epub 2017 Apr 11. Review. PubMed PMID: 28343425.

11: Reiner Ž. Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol. 2017 Jul;14(7):401-411. doi: 10.1038/nrcardio.2017.31. Epub 2017 Mar 16. Review. PubMed PMID: 28300080.

12: Honda Y, Kessoku T, Ogawa Y, Tomeno W, Imajo K, Fujita K, Yoneda M, Takizawa T, Saito S, Nagashima Y, Nakajima A. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep. 2017 Feb 14;7:42477. doi: 10.1038/srep42477. PubMed PMID: 28195199; PubMed Central PMCID: PMC5307366.

13: Hennuyer N, Duplan I, Paquet C, Vanhoutte J, Woitrain E, Touche V, Colin S, Vallez E, Lestavel S, Lefebvre P, Staels B. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. Atherosclerosis. 2016 Jun;249:200-8. doi: 10.1016/j.atherosclerosis.2016.03.003. Epub 2016 Mar 4. PubMed PMID: 27108950.

14: Ishibashi S, Yamashita S, Arai H, Araki E, Yokote K, Suganami H, Fruchart JC, Kodama T; K-877-04 Study Group. Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis. 2016 Jun;249:36-43. doi: 10.1016/j.atherosclerosis.2016.02.029. Epub 2016 Feb 26. PubMed PMID: 27062408.

15: Yamazaki Y, Ogawa S, Shibuya K. Synthesis of highly deuterium-labeled (R)-K-13675, PPAR alpha agonist, for use as an internal standard for low-level quantification of drugs in plasma. Bioorg Med Chem. 2009 Mar 1;17(5):1911-7. doi: 10.1016/j.bmc.2009.01.049. Epub 2009 Feb 13. PubMed PMID: 19217302.

16: Kitajima K, Miura S, Mastuo Y, Uehara Y, Saku K. Newly developed PPAR-alpha agonist (R)-K-13675 inhibits the secretion of inflammatory markers without affecting cell proliferation or tube formation. Atherosclerosis. 2009 Mar;203(1):75-81. doi: 10.1016/j.atherosclerosis.2008.05.055. Epub 2008 Jun 6. PubMed PMID: 18606415.